Xencor, Inc. , a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced corporate priorities and 2026 pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback